Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10211390 | 0.89 | NOTUM (0.46) | NOTUMESR2UCHL1MAPK1NR1H2 | |
| SCHEMBL4666060 | 0.89 | NOTUM (0.43) | NOTUMESR2UCHL1MAPK1NR1H2 | |
| SCHEMBL30195056 | 0.87 | HDAC1 (0.42) | NOTUMESR2UCHL1MAPK1NR1H2 | |
| SCHEMBL553450 | 0.87 | HDAC1 (0.42) | NOTUMESR2UCHL1MAPK1NR1H2 | |
| SCHEMBL619483 | 0.84 | MEN1 (0.48) | NOTUMALDH1A1POLBNPC1RAB9A | |
| SCHEMBL3902271 | 0.83 | CNR2 (0.52) | NOTUMESR2UCHL1MAPK1NR1H2 | |
| SCHEMBL17545408 | 0.83 | NOTUM (0.45) | NOTUMESR2UCHL1MAPK1NR1H2 | |
| SCHEMBL23293654 | 0.82 | NR1H2 (0.46) | NOTUMESR2UCHL1MAPK1NR1H2 | |
| SCHEMBL16123405 | 0.82 | UCHL1 (0.51) | NOTUMESR2UCHL1MAPK1NR1H2 | |
| SCHEMBL31389170 | 0.82 | NR1H2 (0.46) | NOTUMESR2UCHL1MAPK1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119145013-A | Nickel electroplating liquid and preparation method and application thereof | 生益电子股份有限公司 | 2024-12-17 | — | — | CN | claimed |
| CN-119145013-A | Nickel electroplating liquid and preparation method and application thereof | 生益电子股份有限公司 | 2024-12-17 | — | — | CN | disclosed |
| EP-3670515-B1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INST INC (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-109328059-B | Selective inhibitors of clinically important mutants of EGFR tyrosine kinase | CS制药技术有限公司 | 2021-08-17 | — | — | CN | disclosed |
| EP-3738964-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| EP-3670515-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20200071340-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190084998-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-20090318518-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK CANADA INC. (CA) | 2009-12-24 | — | — | US | disclosed |
| US-20090318518-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK CANADA INC. (CA) | 2009-12-24 | — | — | US | disclosed |
| EP-2114877-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Merck Frosst Canada Ltd. (CA) | 2009-11-11 | — | — | EP | disclosed |
| US-20090105321-A1 | Indole Amide Derivatives as Ep4 Receptot Ligands | MERCK CANADA INC. (CA) | 2009-04-23 | — | — | US | disclosed |
| US-20090105321-A1 | Indole Amide Derivatives as Ep4 Receptot Ligands | MERCK CANADA INC. (CA) | 2009-04-23 | — | — | US | disclosed |
| WO-2008104055-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104055-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2008-09-04 | — | — | WO | disclosed |
| WO-2007143825-A1 | INDOLINE AMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK FROSST CANADA LTD. (CA) | 2007-12-21 | — | — | WO | disclosed |
| US-20030105118-A1 | Tricyclic quinazolinediones | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-06-05 | — | — | US | disclosed |
| EP-1288216-A1 | TRICYCLIC QUINAZOLINEDIONES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071340-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | NOTUM 4489/4885ESR2 1641/4885UCHL1 4517/4885 |
| US-20190084998-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | NOTUM 4489/4885ESR2 1641/4885UCHL1 4517/4885 |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | NOTUM 4489/4885ESR2 1641/4885UCHL1 4517/4885 |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | NOTUM 4489/4885ESR2 1641/4885UCHL1 4517/4885 |
| US-20090318518-A1 | INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER3 | NOTUM 2678/4885ESR2 198/4885UCHL1 3898/4885 |
| US-20030105118-A1 | Tricyclic quinazolinediones | PARP1, PARP11, PARP2 | NOTUM 4410/4885ESR2 1932/4885UCHL1 2745/4885 |
| US-20090105321-A1 | Indole Amide Derivatives as Ep4 Receptot Ligands | PTGER4, PTGER1, GPR4 | NOTUM 4319/4885ESR2 88/4885UCHL1 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.